Grant: Banting Postdoctoral Fellowship Program
University of Toronto
$140,000.00
Targeting Colorectal Cancer stem cells self-renewal through EZH2 and PRMT5.
EF 2014-15
Résumé
Colorectal Cancer is one of the major causes of cancer-related death, with almost 50% of the patients relapsing or not responding to the existing treatments. The failure in therapy has been associated with the existence of a small subset of cells existing inside the tumour, which have the capacity to maintain tumour growth: the Cancer Stem Cells. Cancer stem cells are a special kind of cell with the capacity to escape chemotherapy, and possess the ability to renew itself (self-renew), a key feature that allows them to give rise to new tumours. Their resistance to current chemotherapies renders them responsible for cancer relapse. Despite the clinical relevance of Cancer Stem Cells, the mechanism of self-renewal remains unknown and thus hard to target with new drugs. Using patient-derived Cancer Stem cells, we performed a preliminary study suggesting that we might have two possibilities to target the cancer stem cells, using drugs that regulate self-renewal through the change of the "Epigenetics" of cancer stem cells. Epigenetics is an exciting, new area of cancer research, that refers to the regulation of the expression of genes. This new research field holds the potential for brand new ways to design drugs and treat cancer through regulation of self-renewal. Our goal is to understand how our drugs control self-renewal, and if they can constitute new treatments for colon cancer. We will combine the drugs we identified, with the current chemotherapies to see if we can further decrease tumour growth. Hence, our results have the potential to prevent colorectal cancer relapse through the use of "epigenetic" targeting drugs in combination with chemotherapy, and will have huge implications for cancer patients in Canada and around the world.
Programme
Banting Postdoctoral Fellowship Program
Bénéficiaire
Emplacement
Ontario, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database
Tel que publié
Id
315400
Name
Lima Fernandes Evelyne
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Banting Postdoctoral Fellowships Program
Projecttitle
Targeting Colorectal Cancer stem cells self-renewal through EZH2 and PRMT5.
Programtype2
Fellowship Programs
Orgnameinp2
University of Toronto
Cihramount2
$140,000
Cihrequipment2
$0
Programname2
Banting Postdoctoral Fellowship Program
Keyworddelim
Cancer Relapse; Colorectal Cancer Stem Cells; Combination Therapy; Drug Development; Epigenetics; Methylation; Regulation Of Gene Expression; Self-Renewal
Abstract
Colorectal Cancer is one of the major causes of cancer-related death, with almost 50% of the patients relapsing or not responding to the existing treatments. The failure in therapy has been associated with the existence of a small subset of cells existing inside the tumour, which have the capacity to maintain tumour growth: the Cancer Stem Cells. Cancer stem cells are a special kind of cell with the capacity to escape chemotherapy, and possess the ability to renew itself (self-renew), a key feature that allows them to give rise to new tumours. Their resistance to current chemotherapies renders them responsible for cancer relapse. Despite the clinical relevance of Cancer Stem Cells, the mechanism of self-renewal remains unknown and thus hard to target with new drugs. Using patient-derived Cancer Stem cells, we performed a preliminary study suggesting that we might have two possibilities to target the cancer stem cells, using drugs that regulate self-renewal through the change of the "Epigenetics" of cancer stem cells. Epigenetics is an exciting, new area of cancer research, that refers to the regulation of the expression of genes. This new research field holds the potential for brand new ways to design drugs and treat cancer through regulation of self-renewal. Our goal is to understand how our drugs control self-renewal, and if they can constitute new treatments for colon cancer. We will combine the drugs we identified, with the current chemotherapies to see if we can further decrease tumour growth. Hence, our results have the potential to prevent colorectal cancer relapse through the use of "epigenetic" targeting drugs in combination with chemotherapy, and will have huge implications for cancer patients in Canada and around the world.
Competitiondate
201409
Approvedterm2
2 yrs 0 mth
Pinamesdelim
Lima Fernandes, Evelyne
Approvedterm
2 ans 0 mois
Cihrcontribution2
~ $140,000~ $0~